Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.
Strong mid-stage data defy doubts following rival Pfizer’s spin off.
Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
It is make or break time for the smaller group’s TL1A inhibitor PRA023.